[1]聶 志.吸入用沙丁胺醇聯合布地奈德對COPD急性加重期的作用[J].醫學信息,2019,(22):105-106.[doi:10.3969/j.issn.1006-1959.2019.22.033]
 NIE Zhi.Effect of Inhaled Salbutamol Combined with Budesonide on Acute Exacerbation of COPD[J].Medical Information,2019,(22):105-106.[doi:10.3969/j.issn.1006-1959.2019.22.033]
點擊復制

吸入用沙丁胺醇聯合布地奈德對COPD急性加重期的作用()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
105-106
欄目:
臨床研究
出版日期:
2019-11-15

文章信息/Info

Title:
Effect of Inhaled Salbutamol Combined with Budesonide on Acute Exacerbation of COPD
文章編號:
1006-1959(2019)22-0105-02
作者:
聶 志
(贛州市大余縣人民醫院內二科,江西 大余 341500)
Author(s):
NIE Zhi
(Department of Internal Medicine,Subject Two,Dayu County People's Hospital,Dayu 341500,Jiangxi,China)
關鍵詞:
COPD急性加重期沙丁胺醇布地奈德
Keywords:
COPDAcute exacerbation periodSalbutamolBudesonide
分類號:
R563
DOI:
10.3969/j.issn.1006-1959.2019.22.033
文獻標志碼:
A
摘要:
目的 觀察吸入用沙丁胺醇聯合布地奈德對COPD急性加重期的作用。方法 選取2015年1月~2017年1月我院治療的86例COPD急性加重期患者,隨機分為觀察組和對照組,每組43例。對照組在常規治療的基礎上霧化吸入布地奈德,觀察組在對照組的基礎上吸入用沙丁胺醇。比較兩組治療前后用力肺活量(FVC)、第1秒用力呼氣容積(FEV1),臨床治療效果。結果 治療后,兩組FVC、FEV1均高于治療前,觀察組FVC、FEV1分別為(2.08±0.57)L、(1.97±0.43)L,高于對照組的(1.69±0.49)L、(1.47±0.36)L,差異有統計學意義(P<0.05);觀察組治療有效率為97.67%,高于對照組的76.74%,差異有統計學意義(P<0.05)。結論 吸入用沙丁胺醇聯合布地奈德有助于改善COPD急性期患者FVC、FEV1,具有較高的療效。
Abstract:
Objective To observe the effect of inhaled salbutamol combined with budesonide on acute exacerbation of COPD. Methods 86 patients with acute exacerbation of COPD who were admitted to hospital from January 2015 to January 2017 were randomly divided into observation group and control group, with 43 cases in each group. The control group was inhaled budesonide on the basis of conventional treatment, and the observation group inhaled salbutamol on the basis of the control group. The forced vital capacity (FVC) and the forced expiratory volume in the first second (FEV1) before and after treatment were compared between the two groups. Results After treatment, FVC and FEV1 were higher than those before treatment. The FVC and FEV1 of the observation group were (2.08±0.57)L and (1.97±0.43)L, respectively, which was higher than that of the control group (1.69±0.49)L, (1.47±0.36) L, the difference also had statistical significance (P<0.05); the effective rate of observation group was 97.67%, which was higher than 76.74% of the control group, the difference was statistically significant (P<0.05).Conclusion Salbutamol inhalation combined with budesonide can improve the FVC and FEV1 in patients with acute COPD and improve the curative effect. It is worthy of application.

參考文獻/References:

[1]蔡惠東,潘劍蓉.沙丁胺醇聯合布地奈德氧氣霧化吸入與超聲霧化吸入對小兒肺炎療效及炎癥因子的改善對比探析[J].檢驗醫學與臨床,2017,14(18):2745-2747. [2]楊洪濤,陳哲,宋愛芹.霧化吸入布地奈德聯合沙丁胺醇治療慢性阻塞性肺疾病急性加重期的療效及對肺功能相關指標的影響[J].實用臨床醫藥雜志,2017,21(15):118-119. [3]黃誠文,孫印,勾建強,等.正五聚蛋白-3對COPD急性加重期的預測價值[J].國際呼吸雜志,2017,37(21):1614-1617. [4]楊振英,王亞坤,周禮清,等.糖皮質激素類聯合腎上腺素能β激動劑對慢性阻塞性肺疾病急性加重期患者的療效分析[J].安徽醫藥,2018,22(1):151-155. [5]文艷梅,徐治波,茍冶然.甲基潑尼松龍與吸入性布地奈德混懸液對老年COPD急性加重期患者降鈣素原和C反應蛋白水平的影響[J].西部醫學,2017,29(1):78-81. [6]朱;.沙丁胺醇和布地奈德聯合氨溴索霧化治療慢性阻塞性肺疾病急性加重期患者的療效[J].醫療裝備,2017,30(21):125-126.

相似文獻/References:

[1]任慶玲.聚焦解決模式對慢阻肺患者主要照顧者的 照顧負擔及負性情緒影響的研究[J].醫學信息,2018,(07):162.[doi:10.3969/j.issn.1006-1959.2018.07.057]
 REN Qing-ling.Study on the Effect of Focus-resolving Model on the Burden of Care and Negative Emotions of Primary Caregivers in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,(22):162.[doi:10.3969/j.issn.1006-1959.2018.07.057]
[2]林 楊,蘇志強,鮑 靖,等.ICF核心分類聯合mMRC用于COPD患者康復效果的研究[J].醫學信息,2019,(03):175.[doi:10.3969/j.issn.1006-1959.2019.03.060]
 LIN Yang,SU Zhi-qiang,BAO Jing,et al.Effect of ICF Core Classification Combined with mMRC on Rehabilitation of COPD Patients[J].Medical Information,2019,(22):175.[doi:10.3969/j.issn.1006-1959.2019.03.060]
[3]梁雪梅,蔡曉玉,王 真,等.綜合護理措施對無創呼吸機治療COPD合并呼吸衰竭的Meta分析[J].醫學信息,2019,(05):91.[doi:10.3969/j.issn.1006-1959.2019.05.027]
 LIANG Xue-mei,CAI Xiao-yu,WANG Zhen,et al.Meta-analysis of Comprehensive Nursing Measures for Non-invasive Ventilator in the Treatment of COPD with Respiratory Failure[J].Medical Information,2019,(22):91.[doi:10.3969/j.issn.1006-1959.2019.05.027]
[4]劉怡彤,馬利軍.基于“互聯網+”的移動醫療技術在慢性阻塞性肺病穩定期管理的應用及問題研究[J].醫學信息,2019,(06):38.[doi:10.3969/j.issn.1006-1959.2019.06.014]
 LIU Yi-tong,MA Li-jun.Application and Problem Research of Mobile Medical Technology Based on"Internet +"in Stable Period Management of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(22):38.[doi:10.3969/j.issn.1006-1959.2019.06.014]
[5]張佳佳,李 慶,王 同.中性粒細胞CD64指數指導慢性阻塞性肺疾病急性加重期抗生素應用的探討[J].醫學信息,2019,(07):78.[doi:10.3969/j.issn.1006-1959.2019.07.023]
 ZHANG Jia-jia,LI Qing,WANG Tong.The Application of Neutrophil CD64 Index in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(22):78.[doi:10.3969/j.issn.1006-1959.2019.07.023]
[6]吳 鵬,徐 超,曲 紅.線性周期化訓練和非線性周期化訓練對慢性阻塞性肺疾病患者的影響[J].醫學信息,2019,(09):88.[doi:10.3969/j.issn.1006-1959.2019.09.028]
 WU Peng,XU Chao,QU Hong.Effects of Linear Periodic Training and Nonlinear Periodic Training on Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(22):88.[doi:10.3969/j.issn.1006-1959.2019.09.028]
[7]馬宏境,劉 彬.慢性阻塞性肺疾病發病機制的研究[J].醫學信息,2019,(10):50.[doi:10.3969/j.issn.1006-1959.2019.10.018]
 MA Hong-jing,LIU Bin.Study on the Pathogenesis of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(22):50.[doi:10.3969/j.issn.1006-1959.2019.10.018]
[8]高小燕,陳 蓉,盧慧宇.血糖控制水平對COPD伴2型糖尿病患者 肺功能及其預后的影響[J].醫學信息,2019,(16):76.[doi:10.3969/j.issn.1006-1959.2019.16.023]
 GAO Xiao-yan,CHEN Rong,LU Hui-yu.Effect of Blood Glucose Control Level on Pulmonary Function and Prognosis in Patients with COPD and Type 2 Diabetes[J].Medical Information,2019,(22):76.[doi:10.3969/j.issn.1006-1959.2019.16.023]
[9]劉太容,秦爾奇,劉小蘋,等.穴位按摩聯合六字訣呼吸操應用于慢性阻塞性肺疾病 急性加重期患者中的療效[J].醫學信息,2019,(16):151.[doi:10.3969/j.issn.1006-1959.2019.16.051]
 LIU Tai-rong,QIN Er-qi,LIU Xiao-ping,et al.Therapeutic Effect of Acupoint Massage Combined with Six-character Respiration in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,(22):151.[doi:10.3969/j.issn.1006-1959.2019.16.051]
[10]馬建娟.布地奈德聯合異丙托溴銨霧化治療COPD 急性加重期的效果評價[J].醫學信息,2018,(07):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]
 MA Jian-juan.Efficacy Evaluation of Budesonide Combined with Ipratropium Bromide in Treatment of Acute Exacerbation of COPD[J].Medical Information,2018,(22):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩